In 2022, the Office of Inspector General (OIG) and at least two federal courts took a clear stance against pharmaceutical manufacturers’ attempts to offer cost-sharing subsidies to Medicare beneficiaries for certain drugs, despite the thoughtful methods by which these subsidies are being offered. OIG’s stated concerns are consistently increased risk of fraud, usurpation of the legislative function, and price inflation.

However, industry is fighting back. Pharmaceutical manufacturers and lobbying groups are challenging these administrative restrictions in a concerted effort to increase access to life-saving medications.

The Pfizer Saga

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]